Entera Bio Ltd

Research Entera Bio Ltd (ENTX) on Bullrun: market cap USD 81.22M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerENTX
• ExchangeNASDAQ
• CountryIsrael
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 81.22M
• Financial periodFY2025
• RevenueUSD 42.00K
• Revenue growth-76.8%
• Net income-USD 11.44M
• Free cash flow-USD 7.48M
• Gross margin0.0%

Valuation Snapshot

latest market cap is USD 81.22M.

About Entera Bio Ltd

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism;

Frequently asked questions

What is Entera Bio Ltd's market cap?

Entera Bio Ltd's market capitalization is USD 81.22M.

What does Entera Bio Ltd do?

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally.